ABOUT
What’s New in 2024?
With increased viral vector based therapeutics entering clinical trials and nearing IND filing, the need for enhanced process development of viral vector is imminent for biopharma and CDMOs. Aligning with your bottlenecks, the 2nd annual Viral Vector Process Development Europe summit will return to the cell & gene hub in Amsterdam to support you with downstream processing and scale-up capabilities, with quality and regulatory compliance at forefront of mind.
Act now to reduce COGs and improve accessibility and affordability of your novel therapy for patients tomorrow.
What’s In Store in 2024?
15+
Brand new, data-driven case studies shared by Janssen, CSL Behring, Quell Therapeutics on effective viral vector process control & analytics, production at scale, with improved yield and efficiency
3+
Panel and roundtable discussions with like-minded peers to share your day-to-day challenges but spark ideas for solutions to navigate complex partner selection and regulatory landscape
8+
hours of networking with 60+ industry peers and fellow attendees to build your network and relationships
1
Unique opportunity to engage and meet selected industry solution providers for seamless tech transfer and achieve speed-to-market